The mechanism in more detail
Foundational pharmacology work reported that AOD-9604 retains the lipolytic, or fat-releasing, activity of full-length human growth hormone in isolated rat adipocytes, without the anti-lipogenic and diabetogenic signalling associated with the complete hormone. In chronic-treatment studies in obese mice, AOD-9604 reduced fat mass and retained partial lipolytic activity even in mice lacking beta3-adrenergic receptors, suggesting its mechanism is not wholly dependent on that receptor pathway. Across the human trials reviewed, AOD-9604 did not raise IGF-1 levels, distinguishing its reported mechanism of action from growth-hormone-receptor-mediated pathways and from the growth-promoting effects of full-length GH.
This mechanistic profile did not translate into confirmed clinical benefit. The programme’s largest and most rigorous trial, a 24-week, randomised, double-blind, placebo-controlled study (534 enrolled, 502 randomised), did not show a statistically significant fat-loss effect versus placebo at its primary endpoint. AOD-9604 is best understood as a case in which a plausible, well-characterised biological mechanism did not translate into demonstrated clinical efficacy in the best-powered trial conducted. A full peer-reviewed publication of that pivotal trial’s results has not been identified.
Across the six-trial human programme (893 participants pooled), no elevation of IGF-1, no glucose intolerance or insulin resistance, and no antibody formation against AOD-9604 were reported, a consistent tolerability signal confined to short and medium trial durations rather than long-term use.